The Ionis drug is pretty much the same as the Ultragenyx drug (an ASO aimed at releasing paternal UBE3A silencing), so perhaps not surprising it has yielded similar results.
It therefore suffers from the same limitations discussed above, particularly the need for repeated administration by intrathecal injection. NNZ-2591 has a significant advantage being delivered orally if it can match or exceed efficacy.
- Forums
- ASX - By Stock
- Angelman trial
The Ionis drug is pretty much the same as the Ultragenyx drug...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.52 |
Change
0.310(2.04%) |
Mkt cap ! $1.983B |
Open | High | Low | Value | Volume |
$15.19 | $15.62 | $15.11 | $8.655M | 558.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 440 | $15.48 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.54 | 752 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 440 | 15.480 |
1 | 175 | 15.350 |
1 | 708 | 15.210 |
3 | 6677 | 15.200 |
1 | 330 | 15.150 |
Price($) | Vol. | No. |
---|---|---|
15.610 | 5000 | 1 |
15.700 | 250 | 1 |
15.900 | 2000 | 1 |
15.980 | 26038 | 1 |
16.000 | 20 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
NEU (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online